Extended Data Fig. 3: A cryptic transactivation domain (TAD) of EZH2 (EZH2-TAD) directly associates with cMyc and coactivator (p300), promoting malignant growth of leukaemia cells.
(a) Analysis with a prediction software, 9aaTAD, showing two putative TAD sequences (TAD1 and TAD2) within EZH2. Algorithm for the 9aaTAD amino acid pattern was applied in the search, and region clustering conformity was assessed by percentage. (b) Hydrophobicity profile of EZH2-TAD. (c) Luciferase reporter assay using the Gal4 DNA-binding domain (DBD) fusion of EZH2-TAD or VP16-TAD (a potent TAD as a positive control), compared to EV. Y-axis shows relative reporter activation after normalization of signals from an internal control (Renilla luciferase) and then to those of EV-transduced mock (n = 3; mean ± SD; unpaired two-tailed Student’s t-test). *, **, and *** denote the P value of < 0.05, 0.01 and 0.005, respectively. NS denotes not significant. Numerical source data, statistics and exact P values are available as source data.
